# Acadia Pharmaceuticals Type: Company (ACAD) Source: GetYourBrief — https://getyourbrief.com/entity/acadia-pharmaceuticals Canonical HTML page: https://getyourbrief.com/entity/acadia-pharmaceuticals ## Timeline - **2026-03-19**: Earnings Call — Management hosts a conference call to discuss 2025 performance and 2026 outlook. - **2026-03-18**: Financial Reporting — XOMA files Q4 and Full Year 2025 financial results with the SEC. - **2026-02-25**: Q4 Earnings Call — ACADIA reports strong year-end results and 2026 guidance. - **2026-02-02**: Asset Acquisition — Completion of a significant acquisition of royalty rights from a clinical-stage partner. - **2026-01-12**: Strategic Disclosure — XOMA issues Regulation FD disclosure regarding portfolio updates. - **2025-11-15**: Daybue Stix Launch — Launch of the granule formulation to enhance patient compliance. - **2024-12-31**: Fiscal Milestone — ACADIA reports record quarterly revenue and achieves annual GAAP profitability. - **2024-03-11**: Trial Setback — Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint. - **2023-04-15**: Commercial Launch — Daybue officially enters the U.S. market with strong initial uptake. - **2023-03-10**: FDA Approval — Daybue (trofinetide) approved as the first treatment for Rett syndrome. - **2023-03-10**: Daybue Approval — FDA approves Daybue as the first treatment for Rett syndrome. - **2016-05-01**: Nuplazid Approval — FDA approves Nuplazid for Parkinson's disease psychosis. ## Recent coverage (7 stories, network-wide) ### XOMA Royalty Reports Q4 Results as Portfolio Scaling Drives Long-Term Value 2026-03-19 15:43:47 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector. Full story: https://getbiobrief.com/story/xoma-royalty-q4-2025-earnings-analysis ### Parental Demand for Off-Label Autism Treatments Outpaces Clinical Evidence 2026-03-16 12:50:54 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 17 A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe. Full story: https://getbiobrief.com/story/autism-treatment-demand-vs-clinical-evidence ### Alkami Technology Signals Cloud Resilience as Banking SaaS Adoption Accelerates 2026-02-27 12:49:14 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions. Full story: https://getsaasbrief.com/story/alkami-technology-q4-2025-earnings-analysis ### Q4 Earnings Analysis: ACADIA and Alkami Navigate Growth and Market Volatility 2026-02-27 12:48:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 ACADIA Pharmaceuticals and Alkami Technology reported Q4 results that highlight divergent paths for mid-cap growth entities. While ACADIA focuses on the commercial scaling of its rare disease portfolio, Alkami is battling a significant stock correction despite beating revenue expectations. Full story: https://getfinancebrief.com/story/acadia-alkami-q4-earnings-analysis-2026 ### ACADIA Pharmaceuticals Solidifies Rare Disease Leadership in Q4 Results 2026-02-27 12:48:03 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability. Full story: https://getbiobrief.com/story/acadia-pharmaceuticals-q4-2025-earnings-analysis ### ACADIA Pharmaceuticals Q4 Earnings: Rare Disease Pivot Drives Record Growth 2026-02-27 12:47:29 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio. Full story: https://gethealthbrief.com/story/acadia-pharmaceuticals-q4-earnings-rare-disease-growth ### Rare Disease Commercialization and M&A Drive Mid-Cap Biotech Growth 2026-02-26 00:13:15 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 20 Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space. Full story: https://getbiobrief.com/story/biotech-pharma-earnings-analysis-q4-2025 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.